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etabolic Syndrome
ntima-Media
hickness and Beyond*
eatrice A. Golomb, MD, PHD
a Jolla, California
he paper by Dawson et al. (1) in this issue of the Journal
sks: what factors predict or drive the early phases of
therosclerosis, in adolescence and early adulthood, as in-
exed by aortic intima-media thickness (aIMT) and carotid
ntima-media thickness (cIMT)? It uses data from 635
embers of the Muscatine Offspring Study cohort to do so.
nd it leads to an important conclusion.
Metabolic syndrome factors (MSF) predict elevated
IMT and cIMT in adolescence (age 11 to 17 years) and
oung adulthood (age 18 to 34 years). Not all potential risk
actors were evaluated: so-called emerging risk factors were
bsent from consideration (2). In fact, MSF constituted
any of the variables assessed (age, sex, and smoking were
lso measured; among adolescents, smoking was rare and
ow volume).
See page 2273
With this proviso, in adolescents, adjusting for age, sex,
nd height, aIMT was linked to triglycerides, systolic and
iastolic blood pressure (BP), body mass index (BMI), and
aist/hip ratio (WHR); cIMT was linked to systolic BP,
MI, and WHR plus pulse pressure, and heart rate. In
oung adults, aIMT was linked to those 5 predictors from
dolescence, plus high-density lipoprotein (HDL) choles-
erol and pulse pressure. The cIMT was linked to triglyc-
rides, BP, BMI, WHR, hemoglobin A1C, and also total
nd low-density lipoprotein (LDL) cholesterol. High-
ensitivity C-reactive protein, an inflammatory marker
inked to MSF, was not assessed (3).
In multivariable models adjusting for predictors simulta-
eously, not unexpectedly, fewer of these (collinear) vari-
bles were retained. Which variables were preserved, among
uch correlated variables, may depend on details of how the
anual stepwise regression was performed, but here com-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.a
From the Department of Medicine, University of California–San Diego School of
edicine, La Jolla, California.rised BMI and/or WHR for all assessments, and variably
ystolic blood pressure, diastolic blood pressure, or total
holesterol. The finding that MSF are predictors of early
therosclerosis even in youth (whereas LDL cholesterol is
ot), although not surprising, is nonetheless disquieting in
ight of the explosion of metabolic syndrome in childhood
nd afterward (4).
The investigators showed that aIMT (especially in ado-
escents) and cIMT (especially in young adults) correlate to
he PDAY (Pathobiological Determinants of Atherosclero-
is in Youth) score, a coronary risk score devised using
oronary artery and aortic findings on autopsy (age 15 to 34
ears) (5). Both PDAY and IMT look at lesions not at
vents, and predictors similarly emphasize MSF (plus age,
ex, and smoking) (5), so an association is practically
oreordained. The investigators use the correlation, none-
heless, to infer that aIMT and cIMT might substitute for
isk factors in predicting clinical end points (1). However,
he data are not suited to determination of whether either or
oth IMTs add appreciably to prediction for events. That
ust be separately studied.
Several questions pertain:
1. Are these data sufficient to establish the suite of risk
actors for early IMT elevation? No, of course; it is unlikely
hat any single study will be. Many nontraditional risk
actors have been presumptively linked to IMT in childhood
nd early adulthood that were not available for consider-
tion, ranging from hyperhomocysteinemia (6,7) and li-
oprotein(a) (6), to auto-exhaust (6), growth hormone
eficiency (8), and shift work (young adults) (9). Future
tudies should expand the field of inquiry, including factors
otentially proximal to MSF, such as environmental obeso-
ens (10) and pre-natal deprivations (11,12).
2. How should the information be used? Suppose IMT
ere proved to augment risk prediction; at what risk level
ould intervention be merited? And with what interven-
ion? Should detection of lesions in adolescence consign a
hild to a lifetime of drugs? Even among adults, those with
long expected time horizon to events have shown no trend
o benefit with the mainstay of coronary prevention, lipid
reatment, if outcomes that balance risks and benefits to the
atient are considered—all-cause mortality and all-cause
erious morbidity (indexed by the available proxy, all-cause
erious adverse events) (AFCAPS [Air Force/Texas Coro-
ary Atherosclerosis Prevention Study]) (13,14). Is there
eason to suppose that children will fare better? Long-term
rials showing benefit in excess of risk should be a necessary
re-condition to broad pharmaceutical recommendations in
hildhood. Recent randomized trial findings suggesting
otential adverse influences of interventions on sleep (15),
nergy (and interest in activity) (16), and glycemia
17,18)—with prospects for metabolic syndrome implica-
ions—only magnify the need for long-term data firmly
ocumenting predominance of benefit before interventions
re warranted.
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June 16, 2009:2280–2 Metabolic SyndromeWhat, then, of lifestyle recommendations? Recent dietary
ecommendations for lipid management in children, al-
hough observed to take on urgency precisely because of the
pidemic of metabolic syndrome (19), contravene random-
zed trial findings on how best to mitigate MSF. (They
herefore contravene approaches to best mitigate the factors
hat the Dawson et al. [1] study suggests predict atheroscle-
otic risk in young age.) Guidelines advise restricting fat
19), but the randomized A-to-Z trial (20) found that a
igh-fat, high-protein diet significantly improved BMI,
DL, triglycerides, and systolic and diastolic BP over a low
at diet. (The A-to-Z study was not conducted in children,
ut the metabolic principles are expected to be similar, and
o contrary data support a different approach in childhood.)
hese metabolic benefits occurred in the absence of lower
alorie intake or higher energy expenditure.
Of importance, with the “favorable” diet, LDL trended
igher while the total/HDL ratio benefited (20). This is
elevant because analyses show that the total/HDL ratio
ears the full power of the basic lipid profile in cardiac risk
rediction; LDL confers no added prognostic benefit (21).
herefore, others have emphasized that the total/HDL
atio rather than LDL should be the focus of lipid recom-
endations (21,22). Framingham (adults) and PDAY (chil-
ren) coronary risk prediction scores implicitly recognize
his by including total and HDL cholesterol (or, equiva-
ently, non-HDL and HDL) but not LDL cholesterol in
alculating cardiac risk (5,23). Total/HDL but not LDL
holesterol predict cardiovascular risk throughout the lifespan
24–26). The A-to-Z study illustrates that lipid guidelines
ocused on LDL cholesterol—rather than the evidence-
upported total/HDL cholesterol ratio—can impel recom-
endations (here, for macronutrient intake patterns) that,
elative to alternate approaches, may foster MSF and possibly
romote cardiovascular risk (per current evidence and risk
rediction models).
3. Finally, what do the demonstrated associations of risk
actors to early IMT elevations really mean? Even in young
ife, correlation need not imply causation. More primary
actors might drive MSF and atherosclerosis in tandem
with or without MSF also mediating). Oxidative stress
epresents one candidate precursor, powerfully linked to
SF, potentially causally (27,28)—and in turn linked not
ust to heart disease (29) but to the panoply of conditions to
hich metabolic syndrome and diabetes are connected—
uch as depression (30), fatty liver (31), cancer (32), and
ognitive loss (33). There are other such precursors deserv-
ng richer discussion than is possible here. In the context of
xidative stress, it bears note that total and LDL cholesterol
id not emerge as IMT predictors until young adulthood
and then only for cIMT) (1), suggesting that it is not a
ost proximal cause. Because LDL cholesterol transports
ey antioxidants (34–36), one might question whether
DL may increase as an adaptive consequence of other
ausal factors—with or without its own causal implications.I respectfully invoke Golomb’s Law of biology, which
vers that everything in biology is more complicated than
ne thinks it is, even taking into account Golomb’s Law. In
he present case, having established that MSF predict IMT
n early life, it remains to fully define the forces that propel
SF—past merely calories ingested and expended. We
ust understand the battalion of influences that drive the
courge of metabolic syndrome—in childhood, before, and
eyond—the better to battle them.
eprint requests and correspondence: Dr. Beatrice A. Golomb,
CSD School of Medicine, Department of Medicine, 9500
ilman Drive, La Jolla, California 92093-0995. E-mail:
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